These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9456190)

  • 21. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
    Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
    Nielsen D; Jensen JB; Dombernowsky P; Munck O; Fogh J; Brynjolf I; Havsteen H; Hansen M
    J Clin Oncol; 1990 Nov; 8(11):1806-10. PubMed ID: 2230869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study.
    Li X; Guo X; Li J; Yuan L; Wang H
    Medicine (Baltimore); 2022 Aug; 101(32):e30000. PubMed ID: 35960075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Havsteen H; Brynjolf I; Svahn T; Dombernowsky P; Godtfredsen J; Munck O
    Cancer Chemother Pharmacol; 1989; 23(2):101-4. PubMed ID: 2910506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
    Jensen BV; Nielsen SL; Skovsgaard T
    Lancet; 1996 Feb; 347(8997):297-9. PubMed ID: 8569365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
    Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
    J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
    Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
    Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.
    Yu LR; Cao Z; Makhoul I; Daniels JR; Klimberg S; Wei JY; Bai JP; Li J; Lathrop JT; Beger RD; Todorova VK
    Exp Biol Med (Maywood); 2018 Feb; 243(3):248-255. PubMed ID: 29224368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.
    Appel JM; Jensen BV; Nielsen DL; Ryberg M; Zerahn B
    Int J Cardiovasc Imaging; 2010 Feb; 26(2):217-23. PubMed ID: 19823942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
    Daugaard G; Lassen U; Bie P; Pedersen EB; Jensen KT; Abildgaard U; Hesse B; Kjaer A
    Eur J Heart Fail; 2005 Jan; 7(1):87-93. PubMed ID: 15642537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of early epirubicin cardiotoxicity in women with breast cancer.
    Sobić-Saranović D; Pavlović S; Susnjar S; Neskovi c-Konstantinović Z; Jelić S
    Anticancer Res; 1997; 17(5B):3889-91. PubMed ID: 9427798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
    Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
    Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
    Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
    Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy.
    Valdés Olmos RA; ten Bokkel Huinink WW; ten Hoeve RF; van Tinteren H; Bruning PF; van Vlies B; Hoefnagel CA
    Eur J Cancer; 1995; 31A(1):26-31. PubMed ID: 7695974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
    Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
    J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
    Okada Y; Horikawa K; Sano M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):585-9. PubMed ID: 9087292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.